Semaglutide, Tirzepatide, and Retatrutide: a receptor map
A concise comparison of the receptor systems most often associated with three closely discussed research compounds.
These compounds are often discussed together, but their research profiles are not interchangeable.
Target-level comparison
- Semaglutide: GLP-1 receptor research.
- Tirzepatide: GIP and GLP-1 receptor research.
- Retatrutide: GIP, GLP-1, and glucagon receptor research.
That map is a starting point for reading research—not a shortcut to assumptions about efficacy, safety, equivalence, or personal use.
Semaglutide profile · Tirzepatide profile · Retatrutide profile
Use the receptor map as an index
The map helps organize reading, but it does not make these materials substitutes. Begin with the specific research question. Then compare the model, endpoints, reference material and analytical requirements rather than choosing a compound because it has more targets.
Questions to take back to the paper
- Does the experiment measure binding, signalling or a downstream response?
- Are the compared results from the same assay conditions?
- Is the material fully identified, including relevant modifications?
- Does the conclusion stay within the population or model studied?
A useful comparison table has a separate column for “not established.” That makes uncertainty visible instead of turning missing information into an assumed advantage. Published research does not verify the identity or quality of a particular supplier lot.
Related reading
Sources and scope
Sources support the scientific or analytical concepts discussed. They do not certify Reforge products, establish their suitability for a particular study, or imply endorsement by the source organizations. Pharmaceutical guidance is cited for context, not as proof that a research material meets medicinal-product standards.
For laboratory research use only. Not for human or veterinary use.